Townson Sharon 4
4 · Monte Rosa Therapeutics, Inc. · Filed Jan 5, 2026
Insider Transaction Report
Form 4
Townson Sharon
Chief Scientific Officer
Transactions
- Award
Common Stock
2026-01-02+35,000→ 71,000 total - Sale
Common Stock
2026-01-05$15.17/sh−3,155$47,861→ 67,845 total - Award
Stock Option (Right to Buy)
2026-01-02+158,000→ 158,000 totalExercise: $15.31Exp: 2036-01-01→ Common Stock (158,000 underlying)
Footnotes (4)
- [F1]Represents restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 2, 2027, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- [F2]Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.17 to $15.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]25% of this option shall vest and become exercisable on January 2, 2027, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.